课题基金 / 基金详情

ER Co-repressor function of SAFB in Breast Cancer

ER Co-repressor function of SAFB in Breast Cancer
SAFB 在乳腺癌中的 ER 共抑制功能
批准号:
8244698
负责人:
Steffi Oesterreich
金额:
$20.35万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-08-01 至 2011-08-30

项目摘要

项目成果

Steffi Oesterreich的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):我们最初克隆SAFB 1作为转录抑制因子,并且它已经涉及许多过程,包括激素反应和转化。SAFB 1基因在乳腺癌中显示出极高的杂合性丢失率,其丢失与高级别肿瘤和乳腺癌患者生存率降低相关。结构-功能研究确定了一个转录抑制结构域和SAFB 1的过表达钝化雌激素诱导的基因表达和增强雌激素介导的抑制。有趣的是,我们发现SAFB 1的sumoylation是其辅阻遏物活性所必需的。我们产生了SAFB 1-null小鼠,其显示出产前和新生儿致死性,存活的小鼠在生殖系统中具有显著缺陷。为了更深入地了解SAFB 1在ER 1作用中的作用,我们使用SAFB 1 siRNA敲除进行了无偏筛选,然后对雌激素刺激的乳腺癌细胞进行了微阵列分析。该实验揭示了SAFB 1在雌激素介导的基因表达抑制中的重要作用,并鉴定了在雌激素介导的下调中显示完全需要SAFB 1的候选基因。这些候选物包括已知参与迁移、侵袭和存活的蛋白质,例如NEDD 9和骨保护素(OPG)。此外,我们确定了HDAC 7在雌激素介导的一些相同候选基因的抑制中的新作用。因此,我们假设SAFB 1是一个重要的和独特的共调节,是关键的雌激素下调基因,并通过其翻译后修饰介导的抑制sumoylation,至少部分,通过与HDAC 7的相互作用。最后,我们假设SAFB 1介导的靶基因抑制对于其在乳腺肿瘤发生中的作用至关重要,因为抑制的丧失可能导致乳腺癌细胞的迁移、侵袭和存活增加。我们将通过分析SAFB 1如何介导雌激素反应靶基因的转录抑制来测试这些假设,如何通过翻译后修饰来修改其辅助抑制功能,我们将测试其靶基因的抑制是否有助于SAFB 1在乳腺肿瘤发生中的作用。这项工作是非常重要的,因为它将提供深入了解SAFB 1行动的基本机制,这可能有助于改变ER 1行动的范式。虽然ER 1主要被研究为转录激活因子,但同样频繁的雌激素介导的基因表达抑制,特别是辅阻遏物如SAFB 1在这种抑制中的作用,是一个研究不足的领域。最重要的是,我们还将了解SAFB 1的这种抑制活性是否以及如何对其在乳腺肿瘤发生中的作用至关重要。公共卫生相关性:SAFB 1是一种转录辅阻遏物,并且它已经涉及许多细胞过程,包括激素、应答、永生化、凋亡和转化。我们已经发现SAFB 1在雌激素介导的基因表达抑制中起重要作用,这是雌激素受体作用中研究不足但关键的过程。在这里,我们建议研究这种抑制的深入机制,以及这与SAFB 1在乳腺肿瘤发生中的作用有何关系。
英文摘要
DESCRIPTION (provided by applicant): We originally cloned SAFB1 as a transcriptional repressor, and it has since been implicated in a number of processes including hormone response, and transformation. The SAFB1 gene shows extremely high rates of loss of heterozygosity in breast cancer, and its loss is associated with high grade tumors, and reduced survival of breast cancer patients. Structure-function studies identified a transcriptional repression domain and overexpression of SAFB1 blunted estrogen-induction of gene expression and enhanced estrogen-mediated repression. Intriguingly, we found that sumoylation of SAFB1 was necessary for its co-repressor activity. We generated SAFB1-null mice which showed pre- and neonatal lethality, with surviving mice having dramatic defects in the reproductive system. To gain more insight into SAFB1's role in ER1 action, we performed an unbiased screen using SAFB1 siRNA knockdown followed by microarray analysis of estrogen-stimulated breast cancer cells. This experiment revealed a significant role for SAFB1 in estrogen-mediated repression of gene expression, and candidate genes were identified that showed a complete requirement for SAFB1 in estrogen-mediated downregulation. These candidates include proteins known to be involved in migration, invasion, and survival, such as NEDD9 and osteoprotegerin (OPG). Furthermore, we identified a novel role for HDAC7 in estrogen-mediated repression of some of the same candidate genes. We thus hypothesize that SAFB1 is an important and unique co-regulator that is critical for estrogen downregulation of genes, and that the repression is mediated through its posttranslational modification by sumoylation and, at least in part, through interaction with HDAC7. Finally, we hypothesize that SAFB1-mediated repression of its target genes is critical for its role in breast tumorigenesis, since loss of repression might result in increased migration, invasion, and survival of breast cancer cells. We will test these hypotheses by analyzing how SAFB1 mediates transcriptional repression of estrogen-responsive target genes, how is its co-repressor function modified by posttranslational modification, and we will test whether repression of its target genes contributes to SAFB1's role in breast tumorigenesis? This work is highly significant since it will provide insight into fundamental mechanisms of SAFB1 action which may contribute to a change in the paradigm of ER1 action. While ER1 has mainly been studied as a transcriptional activator, the equally frequent estrogen-mediated repression of gene expression, and in particular the role of co-repressors like SAFB1 in this repression, is an understudied area. Most importantly, we will also learn whether and how this repression activity of SAFB1 is critical for its role in breast tumorigenesis. PUBLIC HEALTH RELEVANCE: SAFB1 is a transcriptional co-repressor, and it has since been implicated in a number of cellular processes including hormone, response, immortalization, apoptosis, and transformation. We have discovered that SAFB1 plays a significant role in estrogen- mediated repression of gene expression, which is an understudied yet critical process in estrogen receptor action. Here we propose to study the in-depth mechanism of this repression, and how this relates to SAFB1's role in breast tumorigenesis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
2019 Hormone-Dependent Cancers Gordon Research Conference and Gordon Research Seminar
  • 批准号:
    9760128
  • 项目类别:
  • 资助金额:
    $0.7万
  • 财政年份:
    2019
  • 负责人:
    Steffi Oesterreich
  • 依托单位:
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancer
Mechanism-based strategies to target ER-mutant endocrine resistant breast cancer
FGFR4: A druggable mediator of endocrine resistance in breast cancer
国内基金
海外基金
多孔氮碳负载碱土金属修饰Cu/Cu₂O光催化CO₂还原及机理研究
  • 批准号:
    JCZRLH202601411
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
  • 依托单位:
铜簇负载型MXene催化剂设计及其催化CO₂加氢制甲醇机理的理论研究
  • 批准号:
    2026JJ70020
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    李燕丽
  • 依托单位:
CO2响应型二维多孔Janus催化剂构筑及油/水界面催化调控机制研究
  • 批准号:
    2026JJ80297
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    李超平
  • 依托单位:
光辅助Li-CO2电池中MoS2催化剂性能调控及机理研究
  • 批准号:
    2026JJ90008
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2026
  • 负责人:
    赵亭亭
  • 依托单位: